Neuphoria Therapeutics (NEUP) EPS (Basic) (2023 - 2026)

Neuphoria Therapeutics (NEUP) has reported EPS (Basic) for 4 consecutive years, with -$0.0 the latest figure, recorded in Q1 2026.

• On a quarterly basis, EPS (Basic) fell 104.48% year-over-year to -$0.0 in Q1 2026; TTM through Mar 2026 was -$0.19, a 346.04% decrease from a year earlier, with the FY2025 full-year figure at -$0.05, up 43.15% from the prior year.
• EPS (Basic) was -$0.0 for Q1 2026 at Neuphoria Therapeutics, down from $0.01 in the prior quarter.
• Over five years, EPS (Basic) peaked at $0.09 in Q1 2025 and troughed at -$0.12 in Q2 2025.
• A 4-year average of -$0.02 and a median of -$0.02 in 2024 frame the typical range for EPS (Basic).
• The widest YoY moves for EPS (Basic): up 505.38% in 2025, down 1452.68% in 2025.
• Over 4 years, EPS (Basic) stood at -$0.04 in 2023, then jumped by 57.33% to -$0.02 in 2024, then surged by 195.92% to $0.01 in 2025, then tumbled by 127.09% to -$0.0 in 2026.
• The last three EPS (Basic) figures came in at -$0.0 (Q1 2026), $0.01 (Q4 2025), and -$0.08 (Q3 2025), per Business Quant data.